Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division

BOSTON - July 28, 2023 - PRLog -- Medicilon, a one-stop pharmaceutical preclinical R&D service platform CRO, recognizes the importance of drug discovery as the cornerstone of new drug innovation.

Recently, Medicilon appointed Dr. Liu Jian as the President of Drug Discovery Division.

Dr. Liu Jian holds a Bachelor's degree in Chemistry from Peking University, a Master's degree in Chemical Engineering from Tsinghua University, and a Ph.D. in Computational Chemistry and Organic Chemistry from the University of California, Los Angeles (UCLA). He subsequently conducted postdoctoral research at the University of California, Irvine, and the University of Pennsylvania.  In 2018, Dr. Liu Jian served as the President of the Sino-American Pharmaceutical Professionals Association (SAPA) and is currently the Chairman of the board of directors of SAPA.  In 2019, he was awarded the "Outstanding 50 Asian American in Business " by the Asian-American Business Development Center in New York and was elected as one of the 12 most influential Chinese-Americans in New Jersey in 2019.

Medicilon's Drug Discovery Services: https://www.medicilon.com/platform/drug-discovery/